Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The beauty giant said the transaction – selling approximately 29.6 million of its Sanofi shares for €101.5 per share – will ...